Despite early positive clinical data that proposed the use of Drotrecogin alfa (Xigris®; a recombinant form of APC) as a therapeutic intervention for sepsis and septic shock, the medicine was withdrawn due to the lack of replication in subsequent trials and its associated risk of bleeding58. This evidence concerns the gene APC and Sepsis.